Systematic review/Meta-analysis A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience

Keshavarz, Khosro; Hashemi-Meshkini, Amir; Gharibnaseri, Zahra; Nikfar, Shekoufeh; Kebriaeezadeh, Abbas; Abdollahi, Mohammad

doi:10.5114/aoms.2013.39617

Cited by 7 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Future interventional studies, i.e. generic treatments such as pregabalin [35] or specific interventions such as foot trigger points dry needling [36, 37] and custom-made foot orthotics [38] in women with fibromyalgia, could use these clinical differences as key references in order to normalize the specific foot and general health-related quality of life. In line with prior research [8], we highlight that health authorities should pay more attention to improving the general and foot specific health-related quality of life in women with fibromyalgia.…”

Section: Discussionmentioning

confidence: 99%

Quality of life related to foot health status in women with fibromyalgia: a case-control study

Palomo‐López¹,

Calvo‐Lobo²,

Becerro-de-Bengoa-Vallejo³

et al. 2019

aoms

View full text Add to dashboard Cite

Introduction To date, the Foot Health Status Questionnaire (FHSQ) has not been applied to women who suffer from fibromyalgia. The main purpose of this study was to compare both foot and general health-related quality of life between women with fibromyalgia and healthy matched women. We hypothesized that women with fibromyalgia may present an impaired quality of life related to foot and general health. Material and methods A sample of 208 women, mean age of 55.00 ±8.25 years, was recruited from an outpatient clinic and divided into 2 groups, 104 women with fibromyalgia (for the case group) and 104 healthy matched women (for the control group). Demographic data and the domains of the FHSQ scores were registered. Results Statistically significant differences ( p < 0.001) between case and control groups were found for both all specific foot domains (pain, foot function, foot health and footwear) and all general wellbeing domains (general health, physical activity, social capacity and vigor), showing a worse foot and general health-related quality of life (with lower scores for all FHSQ domains) in the women with fibromyalgia compared to healthy matched women. Conclusions Impaired foot and general health-related quality of life was observed in women who suffered from fibromyalgia compared to healthy matched women.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of life related to foot health status in women with fibromyalgia: a case-control study

Palomo‐López¹,

Calvo‐Lobo²,

Becerro-de-Bengoa-Vallejo³

et al. 2019

aoms

View full text Add to dashboard Cite

show abstract

“…In both studies, 58 , 59 the incremental cost-effectiveness ratios with pregabalin therapy was highest in patients with severe fibromyalgia and with 450 mg/day dosage. Studies from Iran 61 and Mexico 62 revealed consistent effects on cost saving, with most benefit with pregabalin 450 and 600 mg/day. 61 Comparative analyses of pregabalin and other drugs in fibromyalgia, especially duloxetine, have not always revealed consistent results with some studies pointing toward higher health care resource use with pregabalin, probably driven by more inpatient and outpatient visits and medication use, while others revealed nonsignificant difference between the two.…”

Section: Burden Of Fibromyalgiamentioning

confidence: 87%

“…Studies from Iran 61 and Mexico 62 revealed consistent effects on cost saving, with most benefit with pregabalin 450 and 600 mg/day. 61 Comparative analyses of pregabalin and other drugs in fibromyalgia, especially duloxetine, have not always revealed consistent results with some studies pointing toward higher health care resource use with pregabalin, probably driven by more inpatient and outpatient visits and medication use, while others revealed nonsignificant difference between the two. 63 Almost all cost-effectiveness analyses are dominated by amitriptyline because of its lower costs but the comparison between amitriptyline and pregabalin relies on older studies which may not meet current quality criteria 59 and the degree of overall clinical improvement (reduction of VAS score by >50% and decrease in FIQ score by 30%) is lower with amityrptyline.…”

Section: Burden Of Fibromyalgiamentioning

confidence: 87%

Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia

Bhusal¹,

Diomampo²,

Magrey³

2016

DHPS

View full text Add to dashboard Cite

Fibromyalgia is a chronic debilitating medical syndrome with limited therapeutic options. Pregabalin, an anticonvulsant and α-2-Δ subunit receptor ligand, is one of the anchor drugs approved by the US Food and Drug Administration for the treatment of fibromyalgia. The drug has shown clinically meaningful benefits across multiple symptom domains of fibromyalgia. Efficacy of pregabalin in fibromyalgia pain has been evaluated in at least five high-quality randomized trials, two long-term extension studies, a meta-analysis, a Cochrane database systematic review, and several post hoc analyses. These studies also hint towards a meaningful benefit on sleep, functioning, quality of life, and work productivity. Side effects of pregabalin, although common, are mild to moderate in intensity. They are noted early during therapy, improve or disappear with dose reduction, and are not usually life- or organ threatening. In most patients, tolerance develops to the most common side effects, dizziness, and somnolence, with time. With close clinical monitoring at initiation or dose titration, pregabalin can be effectively used in primary care setting. Pregabalin is cost saving with long-term use and its cost-effectiveness profile is comparable, if not better, to that of other drugs used in fibromyalgia. In the present era of limited therapeutic options, pregabalin undoubtedly retains its role as one of cardinal drugs used in the treatment of fibromyalgia. This review intends to discuss the clinical utility of pregabalin in the management of fibromyalgia with a focus on efficacy, safety, and cost-effectiveness.

show abstract

“…The first diagnostic criteria for fibromyalgia were published in 1990, defining chronic widespread pain with a number of tender points; however, newer classification criteria for fibromyalgia were proposed in 2010 [2][3][4][5]. Various drugs at different doses, such as amitriptyline, pregabalin, gabapentin, and duloxetine, are used in the treatment [6]. The aetiology of the disease is still not clearly understood.…”

Section: Introductionmentioning

confidence: 99%

Dynamic thiol and disulphide homoeostasis in fibromyalgia

Karataş¹,

Gündüz²,

Haskul³

et al. 2020

aoms

View full text Add to dashboard Cite

Introduction: Thiol and disulphide levels are biomarkers that provide useful information about oxidative stress and antioxidant capacity, showing a different homoeostasis in inflammatory and proliferative diseases. We aimed to clarify the possible aetiology of this disease by using thiol and disulphide levels in patients with fibromyalgia, the basis of which has not yet been clearly elucidated. Material and methods: A total of 156 individuals: 86 patients with fibromyalgia and 70 age-matched controls were included in this prospective non-randomised case-control study. Demographic characteristics including smoking status, body mass index (BMI), the duration of complaints, and pain levels were carefully recorded. Dynamic thiol-disulphide homoeostasis in blood samples was determined by an automatic-spectrophotometric method. The Mann-Whitney U and Student's t-test were used to determine the differences between the groups. Results: Sex, BMI, and smoking status were similar between the groups (p = 0.62, p = 0.09, and p = 0.64, respectively). While native thiol levels were found to be high in patients with fibromyalgia (p = 0.018), disulphide levels and the rates of disulphide/native thiol and disulphide/total thiol were significantly low (p = 0.049, p = 0.007, and p = 0.007, respectively). Correlation analysis showed no significant relationship between thiol-disulphide levels and duration of complaints or pain level. Conclusions: Thiol-disulphide balance in fibromyalgia was found to be similar to benign proliferative diseases, suggesting that the underlying mechanism is more likely to be of proliferative pattern rather than inflammatory. Additionally, fibromyalgia is not directly associated with increase in oxidative stress. The molecular mechanisms need to be elucidated.

show abstract

Systematic review/Meta-analysis A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience

Cited by 7 publications

References 22 publications

Quality of life related to foot health status in women with fibromyalgia: a case-control study

Quality of life related to foot health status in women with fibromyalgia: a case-control study

Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia

Dynamic thiol and disulphide homoeostasis in fibromyalgia

Contact Info

Product

Resources

About